Outcomes of Septal Myectomy on Patients with Hypertrophic Cardiomyopathy
Caitlin Hoeing, James K. Wu
Lehigh Valley Health Network, Allentown, PA, USA
Objective Septal myectomy is a very prevalent procedure for patients with hypertrophic cardiomyopathy (HCM). Previous studies have found promising outcomes that include low mortality rates and rare occurrences of major complications. This study seeks to evaluate the survival rates of patients with HCM that underwent the septal myectomy procedure. It also seeks to understand postoperative complications of the surgery.
Methods This study is a single-center retrospective review of all septal myectomy patients from 2006-2020 at a local health network. The in-house database containing medical records was utilized to assess patient outcomes. A unique database was created to record and analyze data through descriptive statistics.
Results A cohort of 114 patients over 14 years was assessed. Out of 114 patients that had HCM and underwent septal myectomy, 14 patients died (12.28%). The average survival time was 1,134.14 days. The largest complication post-operation was the need for a new pacemaker (10 patients, 8.7%).
|Factor||Number of eventsa||Number censoredb||Total sample size|
Table 1: Septal Myectomy Patient Mortality SummaryEvents = Death Censored = AliveConclusions Patients with multiple comorbidities are at higher risk for the septal myectomy procedure. Despite the higher risk for those patients, their survival rates are good. The survival rates demonstrate that the septal myectomy procedure is a safe, effective solution for HCM. Complications can occur. However, the data is significant in that these complications are at a low prevalence in the patient population. Long-term survival rates for HCM patients illustrate success for septal myectomy.
Back to 2020 Program